A novel PET imaging using 64cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Kobayashi, Kazuko ^a   Sasaki, Takanori ^a   Takenaka, Fumiaki ^a   Yakushiji, Hiromasa ^a   Fujii, Yoshihiro ^b   Kishi, Yoshiro ^b   Kita, Shoichi ^b   Shen, Lianhua ^a,c   Kumon, Hiromi ^a   Matsuura, Eiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Medical & Biological Laboratories Co Ltd   (Japan)

^c SHIMADZU CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; RADIOPHARMACEUTICAL AGENT; TETRAXETAN 11 25 MONOCLONAL ANTIBODY CU 64; UNCLASSIFIED DRUG; COPPER; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG BINDING; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; DIAGNOSTIC IMAGING; IMMUNOLOGY; NUDE MOUSE; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COPPER; GPI-LINKED PROTEINS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84927127812     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/268172     Document Type: Article

References (46)

1. K. Chang, I. Pastan, and M. C. Willingham,"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium," International Journal of Cancer, vol. 50, no. 3, pp. 373-381, 1992.
2. R. Hassan, T. Bera, and I. Pastan,"Mesothelin: a new target for immunotherapy," Clinical Cancer Research, vol. 10, no. 12, pp. 3937-3942, 2004.
3. R. Hassan and M. Ho,"Mesothelin targeted cancer immunotherapy," European Journal of Cancer, vol. 44, no. 1, pp. 46-53, 2008.
4. P. Argani, C. Iacobuzio-Donahue, B. Ryu et al.,"Mesothelin is overexpressed in the vastmajority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE)," Clinical Cancer Research, vol. 7, no. 12, pp. 3862-3868, 2001.
5. K. Baba, S. Ishigami, T. Arigami et al.,"Mesothelin expression correlates with prolonged patient survival in gastric cancer," Journal of Surgical Oncology, vol. 105, no. 2, pp. 195-199, 2012.
6. R. Hassan, R. J. Kreitman, I. Pastan, and M. C. Willingham,"Localization of mesothelin in epithelial ovarian cancer," Applied Immunohistochemistry & Molecular Morphology, vol. 13, no. 3, pp. 243-247, 2005.
7. N. G. Ordóñez,"Application of mesothelin immunostaining in tumor diagnosis," The American Journal of Surgical Pathology, vol. 27, no. 11, pp. 1418-1428, 2003.
8. N. G. Ordóñez,"Value of mesothelin immunostaining in the diagnosis of mesothelioma," Modern Pathology, vol. 16, no. 3, pp. 192-197, 2003.
9. J. Tchou, L.-C. Wang, B. Selven et al.,"Mesothelin, a novel immunotherapy target for triple negative breast cancer," Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 799-804, 2012.
10. K. Chang and I. Pastan,"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 1, pp. 136-140, 1996.
11. L. A. Dainty, J. I. Risinger, C. Morrison et al.,"Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma," Gynecologic Oncology, vol. 105, no. 3, pp. 563-570, 2007.
12. D. Steinbach, M. Onda, A. Voigt et al.,"Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells," European Journal of Haematology, vol. 79, no. 4, pp. 281-286, 2007.
13. L. Yu, M. Feng, H. Kim et al.,"Mesothelin as a potential therapeutic target in human cholangiocarcinoma," Journal of Cancer, vol. 1, no. 1, pp. 141-149, 2010.
14. T. K. Bera and I. Pastan,"Mesothelin is not required for normal mouse development or reproduction," Molecular and Cellular Biology, vol. 20, no. 8, pp. 2902-2906, 2000.
15. Z. Tang, M. Qian, and M. Ho,"The role of mesothelin in tumor progression and targeted therapy," Anti-Cancer Agents in Medicinal Chemistry, vol. 13, no. 2, pp. 276-280, 2013.
16. J. A. A. Gubbels, J. Belisle, M. Onda et al.,"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors," Molecular Cancer, vol. 5, article 50, 2006.
17. R. Hassan, C. Schweizer, K. F. Lu et al.,"Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy," Lung Cancer, vol. 68, no. 3, pp. 455-459, 2010.
18. A. Shimizu, S. Hirono, M. Tani et al.,"Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma," Cancer Science, vol. 103, no. 4, pp. 739-746, 2012.
19. M. C. Chang, C. A. Chen, P. J. Chen et al.,"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways," Biochemical Journal, vol. 442, no. 2, pp. 293-302, 2012.
20. E. L. Servais, C. Colovos, L. Rodriguez et al.,"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients," Clinical Cancer Research, vol. 18, no. 9, pp. 2478-2489, 2012.
21. U. Bharadwaj, C. Marin-Muller, M. Li, C. Chen, and Q. Yao,"Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression," Molecular Cancer, vol. 10, article 106, 2011.
22. U. Bharadwaj, C. Marin-Muller, M. Li, C. Chen, and Q. Yao,"Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation," Carcinogenesis, vol. 32, no. 7, pp. 1013-1024, 2011.
23. M.-C. Chang, C.-A. Chen, C.-Y. Hsieh et al.,"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway," Biochemical Journal, vol. 424, no. 3, pp. 449-458, 2009.
24. W.-F. Cheng, C.-Y. Huang, M.-C. Chang et al.,"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma," British Journal of Cancer, vol. 100, no. 7, pp. 1144-1153, 2009.
25. M. Ho, M. Feng, R. J. Fisher, C. Rader, and I. Pastan,"A novel high-affinity humanmonoclonal antibody tomesothelin," International Journal of Cancer, vol. 128, no. 9, pp. 2020-2030, 2011.
26. K. Iwahori, T. Osaki, S. Serada et al.,"Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin," LungCancer, vol. 62, no. 1, pp. 45-54, 2008.
27. A. M. Wu and P. D. Senter,"Arming antibodies: prospects and challenges for immunoconjugates," Nature Biotechnology, vol. 23, no. 9, pp. 1137-1146, 2005.
28. P. J. Blower, J. S. Lewis, and J. Zweit,"Copper radionuclides and radiopharmaceuticals in nuclear medicine," Nuclear Medicine and Biology, vol. 23, no. 8, pp. 957-980, 1996.
29. T. Toyota, T. Hanafusa, T. Oda et al.,"A purification system for 64Cu produced by a biomedical cyclotron for antibody PET imaging," Journal of Radioanalytical and Nuclear Chemistry, vol. 298, no. 1, pp. 295-300, 2013.
30. W. P. Li, L. A. Meyer, D. A. Capretto, C. D. Sherman, and C. J. Anderson,"Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors," Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 2, pp. 158-171, 2008.
31. R. Hassan, C. Wu, M. W. Brechbiel, I. Margulies, R. J. Kreitman, and I. Pastan,"111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin," International Journal of Cancer, vol. 80, no. 4, pp. 559-563, 1999.
32. N. Scholler, N. Fu, Y. Yang et al.,"Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 20, pp. 11531-11536, 1999.
33. J. Creaney, R. J. Francis, I. M. Dick et al.,"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden," Clinical Cancer Research, vol. 17, no. 5, pp. 1181-1189, 2011.
34. U. Bharadwaj, M. Li, C. Chen, and Q. Yao,"Mesothelininduced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3," Molecular Cancer Research, vol. 6, no. 11, pp. 1755-1765, 2008.
35. J. Fredebohm, M. Boettcher, C. Eisen et al.,"Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system," PLoS ONE, vol. 7, no. 11, Article ID e48503, 2012.
36. M. Li, U. Bharadwaj, R. Zhang et al.,"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer," Molecular Cancer Therapeutics, vol. 7, no. 2, pp. 286-296, 2008.
37. M. Miyazawa, M. Iwahashi, T. Ojima et al.,"Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro," Cancer Letters, vol. 305, no. 1, pp. 32-39, 2011.
38. R. Hassan, Z. G. Laszik, M. Lerner, M. Raffeld, R. Postier, and D. Brackett,"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis," American Journal of Clinical Pathology, vol. 124, no. 6, pp. 838-845, 2005.
39. S. Lutje, M. Rijpkema, G. M. Franssen et al.,"Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody," Journal of Nuclear Medicine, vol. 55, no. 6, pp. 995-1001, 2014.
40. W. Ping Li, L. A. Meyer, D. A. Capretto, C. D. Sherman, and C. J. Anderson,"Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors," Cancer Biotherapy and Radiopharmaceuticals, vol. 23, no. 2, pp. 158-171, 2008.
41. M. Eiblmaier, L. A. Meyer, M. A. Watson, P. M. Fracasso, L. J. Pike, and C. J. Anderson,"Correlating EGFR expression with receptor-binding properties and internalization of 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines," Journal of Nuclear Medicine, vol. 49, no. 9, pp. 1472-1479, 2008.
42. C. Yoshida, C. Sogawa, A. B. Tsuji et al.,"Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model," Nuclear Medicine Communications, vol. 31, no. 5, pp. 380-388, 2010.
43. J. E. Mortimer, J. R. Bading, D. M. Colcher et al.,"Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET," Journal of Nuclear Medicine, vol. 55, no. 1, pp. 23-29, 2014.
44. K. Tamura, H. Kurihara, K. Yonemori et al.," 64Cu-DOTAtrastuzumab PET imaging in patients with HER2-positive breast cancer," Journal of Nuclear Medicine, vol. 54, no. 11, pp. 1869-1875, 2013.
45. C. J. Anderson, J. M. Connett, S. W. Schwarz et al.,"Copper-64-labeled antibodies for PET imaging," Journal of Nuclear Medicine, vol. 33, no. 9, pp. 1685-1691, 1992.
46. D. J. Slamon, G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire,"Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene," Science, vol. 235, no. 4785, pp. 177-182, 1987.